TG Therapeutics, Inc.
TGTX
$35.75
-$0.75-2.06%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
10/9/2025
-
MarketBeat
10/8/2025
-
MarketBeat
10/8/2025
-
Tickeron - Stocks
10/7/2025
-
Ticker Report
10/7/2025
-
MarketBeat
10/7/2025
-
MarketBeat
10/6/2025
-
The Fly
10/5/2025
-
Simply Wall St
10/3/2025
-
Simply Wall St
10/3/2025
-
ETF Channel
10/2/2025
-
Tickeron - Stocks
10/1/2025
-
Tickeron - Stocks
9/30/2025
-
Simply Wall St
TG Therapeutics (TGTX) Is Up 9.7% After Six-Year BRIUMVI MS Data Shows Sustained Efficacy and Safety
9/27/2025
-
Simply Wall St
9/27/2025
-
Tickeron - Stocks
9/26/2025
-
Tickeron - Technical Analysis
9/24/2025
-
Globe Newswire
9/23/2025
-
Tickeron - Technical Analysis
9/23/2025
-
Tickeron - Technical Analysis
9/22/2025
-
Nasdaq News: Markets
9/22/2025
-
Market News Video
9/22/2025
-
Simply Wall St
9/20/2025
-
MarketBeat
9/18/2025
-
MarketBeat
9/18/2025
-
MarketBeat
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, August 8, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
212 554 4484
Address
3020 Carrington Mill Blvd.
Morrisville, NC 27560
Morrisville, NC 27560
Country
Year Founded
Business Description
Sector
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United...
more